Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CATX Perspective Therapeutics	$3.36 -0.7%	$3.79	$1.60 ▼ $16.31	$248.41M	1.17	927,023 shs	363,263 shs
HAIR Restoration Robotics	$2.31 +1.1%	$2.27	$0.37 ▼ $0.43	$94.18M	4.26	167,778 shs	35,002 shs
INFU InfuSystem	$10.77 +0.4%	$7.11	$4.61 ▼ $11.04	$220.13M	1.81	176,059 shs	273,495 shs
NSPR InspireMD	$2.43 +0.2%	$2.42	$1.99 ▼ $3.80	$101.17M	0.6	103,077 shs	28,964 shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CATX Perspective Therapeutics	-6.37%	-5.06%	-13.78%	+31.52%	-77.87%
HAIR Restoration Robotics	-9.88%	-3.39%	-10.24%	-2.15%	+294.19%
INFU InfuSystem	+3.77%	+11.65%	+83.11%	+85.64%	+65.84%
NSPR InspireMD	-0.82%	+2.11%	-0.82%	-4.35%	-14.79%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CATX Perspective Therapeutics	1.3854 of 5 stars	3.6	1.0	0.0	0.0	1.6	0.8	0.0
HAIR Restoration Robotics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	2.6072 of 5 stars	1.0	5.0	0.0	0.0	2.6	4.2	1.9
NSPR InspireMD	3.4053 of 5 stars	3.5	5.0	0.0	0.0	0.6	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CATX Perspective Therapeutics	3.18	Buy	$12.56	274.23% Upside
HAIR Restoration Robotics	0.00	N/A	N/A	N/A
INFU InfuSystem	4.00	Strong Buy	$12.50	16.06% Upside
NSPR InspireMD	3.00	Buy	$4.50	85.57% Upside

Current Analyst Ratings Breakdown

Latest HAIR, CATX, INFU, and NSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/22/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
7/21/2025	INFU InfuSystem	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/12/2025	CATX Perspective Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/23/2025	CATX Perspective Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $12.00
6/23/2025	CATX Perspective Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$11.00
6/3/2025	CATX Perspective Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$15.00 ➝ $16.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	$2.67 per share	N/A
HAIR Restoration Robotics	$21.96M	4.29	N/A	N/A	$0.04 per share	57.63
INFU InfuSystem	$139.89M	1.57	$0.84 per share	12.79	$2.47 per share	4.36
NSPR InspireMD	$7.07M	14.32	N/A	N/A	$1.83 per share	1.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CATX Perspective Therapeutics	-$46.51M	N/A	0.00	N/A	N/A	-4,096.66%	-27.40%	-23.16%	11/11/2025 (Estimated)
HAIR Restoration Robotics	-$28.73M	-$0.86	N/A	N/A	N/A	-153.44%	-1,908.92%	-99.86%	N/A
INFU InfuSystem	$870K	$0.23	179.65	34.74	N/A	1.12%	2.78%	1.41%	N/A
NSPR InspireMD	-$19.92M	-$0.83	N/A	N/A	N/A	-413.96%	-69.42%	-57.68%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CATX Perspective Therapeutics	N/A	N/A	N/A	N/A	N/A
HAIR Restoration Robotics	N/A	N/A	N/A	N/A	N/A
INFU InfuSystem	N/A	N/A	N/A	N/A	N/A
NSPR InspireMD	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CATX Perspective Therapeutics	N/A	9.60	9.60
HAIR Restoration Robotics	N/A	1.48	1.03
INFU InfuSystem	0.50	1.98	1.59
NSPR InspireMD	N/A	6.39	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CATX Perspective Therapeutics	54.66%
HAIR Restoration Robotics	17.55%
INFU InfuSystem	71.13%
NSPR InspireMD	44.78%

Insider Ownership

Company	Insider Ownership
CATX Perspective Therapeutics	3.72%
HAIR Restoration Robotics	37.80%
INFU InfuSystem	11.40%
NSPR InspireMD	29.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CATX Perspective Therapeutics	70	74.26 million	65.21 million	Optionable
HAIR Restoration Robotics	102	40.86 million	N/A	Not Optionable
INFU InfuSystem	410	20.43 million	19.10 million	Optionable
NSPR InspireMD	50	41.72 million	18.33 million	Optionable

HAIR, CATX, INFU, and NSPR Headlines

Recent News About These Companies

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

August 27 at 9:00 AM | globenewswire.com

InspireMD Rings the Closing Bell

August 25, 2025 | nasdaq.com

Contrasting InfuSystem (NYSE:INFU) & InspireMD (NYSE:NSPR)

August 25, 2025 | americanbankingnews.com

InspireMD’s Earnings Call: FDA Approval and Financial Challenges

August 15, 2025 | theglobeandmail.com

InspireMD, Inc. (NASDAQ:NSPR) Q2 2025 Earnings Call Transcript

August 6, 2025 | msn.com

InspireMD, Inc. (NSPR) Q2 2025 Earnings Call Transcript

August 6, 2025 | seekingalpha.com

InspireMD Reports Second Quarter 2025 Financial Results

August 5, 2025 | globenewswire.com

InspireMD Q2 2025 Earnings Preview

August 4, 2025 | msn.com

What to Expect from InspireMD Inc (NSPR) Q2 2025 Earnings

August 4, 2025 | finance.yahoo.com

Investors in InspireMD (NASDAQ:NSPR) from five years ago are still down 60%, even after 11% gain this past week

August 3, 2025 | finance.yahoo.com

InspireMD, Inc. (NYSE:NSPR) CEO Marvin Slosman Acquires 10,330 Shares

August 2, 2025 | marketbeat.com

InspireMD, Inc. (NYSE:NSPR) Director Paul Stuka Acquires 20,661 Shares

August 2, 2025 | marketbeat.com

Thomas J. Kester Acquires 30,991 Shares of InspireMD, Inc. (NYSE:NSPR) Stock

August 2, 2025 | marketbeat.com

InspireMD, Inc. (NYSE:NSPR) Director Acquires $99,999.24 in Stock

August 2, 2025 | marketbeat.com

Marvin Slosman Acquires 10,330 Shares of InspireMD, Inc. (NYSE:NSPR) Stock

August 2, 2025 | insidertrades.com

InspireMD brings in $58M, adds former Axonics CEO to board

July 31, 2025 | massdevice.com

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

July 31, 2025 | globenewswire.com

InspireMD Announces Combined Financings of $58 Million

July 31, 2025 | globenewswire.com

InspireMD to Announce Second Quarter 2025 Financial Results

July 22, 2025 | globenewswire.com

InspireMD Launches CGuard Prime Carotid Stent System in the U.S.

July 11, 2025 | zacks.com

InspireMD’s CGuard Prime Carotid Stent System Launched in United States

July 10, 2025 | evtoday.comE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HAIR, CATX, INFU, and NSPR Company Descriptions

Perspective Therapeutics NYSE:CATX

$3.36 -0.03 (-0.74%)

As of 03:53 PM Eastern

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Restoration Robotics NASDAQ:HAIR

Restoration Robotics, Inc., a medical device company, develops and commercializes image-guided robotic systems in the United States and internationally. The company offers ARTAS System, a physician-assisted robotic system that identifies and dissects hair follicular units directly from the scalp and creates recipient implant sites. Its system includes the ARTAS Hair Studio application, an interactive three-dimensional patient consultation tool that enables a physician to create a simulated hair transplant model for use in patient consultations. The company was founded in 2002 and is headquartered in San Jose, California.

InfuSystem NYSE:INFU

$10.77 +0.04 (+0.37%)

As of 03:53 PM Eastern

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.

InspireMD NYSE:NSPR

$2.42 +0.01 (+0.21%)

As of 03:49 PM Eastern

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time